Law360, New York (November 02, 2011, 6:39 PM ET) -- Cephalon Inc. accused Breckenridge Pharmaceutical Inc. on Wednesday of infringing a patent for Nuvigil in its latest Delaware federal court attempt to keep generic-drug makers from selling versions of the narcolepsy drug before the patent expires.
The complaint stems from an abbreviated new drug application that the Boca Raton, Fla.-based Breckenridge, along with fellow defendant Natco Ltd., filed with the U.S. Food and Drug Administration seeking approval to market its own version of the armodafinil treatment.
Along with the ANDA, Breckenridge and India-based Natco also filed...
Cephalon Targets Breckenridge Over Nuvigil Patent
To view the full article, take a free trial now.
